Back to top

LACOG 1918

  /    /  LACOG 1918

Patient Journey with advanced lung cancer positive for ALK fusion in Brazil

Type of Study: Epidemiological

Sponsor / Support: LACOG, GBOT, Takeda

Primary Objectives: The general objective of this study is to describe the treatment sequencing of ALK-positive advanced NSCLC in a real-world setting.

Design: An observational, retrospective cohort study

Sample Size: 100 patients

Principal Investigator: Eldsamira Mascarenhas

Countries LATAM: Brazil

Clinicaltrials.gov Identifier: NCT04947683

The study is open to patients participation in the following research sites:

A.C. Camargo Câncer Center / São Paulo / SP / Brazil

LIGA / Natal / RN / Brazil

IDOR - Instituto D'Or de Ensino e Pesquisa / Rio de Janeiro / RJ / Brazil

CPO-RS - Centro de Pesquisa em Oncologia / Porto Alegre / RS / Brazil

CRIO - Centro Regional Integrado de Oncologia / Fortaleza / CE / Brazil